Recombinant DNA Technology Market Highlights
The recombinant DNA technology is a process that manipulates and alters the DNA sequences, resulting in a genetically modified organism and product. These genetically modified products or organisms have superior or specific ability such as resistance to certain chemicals, high productivity, and survival abilities in harsh conditions (GM crops).
The global recombinant DNA technology market is expected to grow at a CAGR of approximately 6.9% during the forecast period, 2017–2023.
The recombinant DNA technology has a practical application of biotechnology in the fields of applied immunology, genomics, diagnostic tools, and development of pharmaceutical therapeutics. There are numerous biological methods used to create a recombinant DNA. The treatment was developed for leukemia disorder, in conjugation between the Novartis Corp and the University of Pennsylvania.
Inquire for Sample Research Report https://www.marketresearchfuture.com/sample_request/5845
Industry Segmentation
The global recombinant DNA technology market is segmented on the basis of product, component, application, and end-user.
On the basis of product, the global recombinant DNA technology market is segmented into medical, non-medical, and others. The medical segment is divided into therapeutic agent, human protein, and vaccines. The non-medical segment is divided into biotech crops, specialty chemicals, and others.
On the basis of component, the global recombinant DNA technology market is segmented into expression system, cloning vector, and others. The expression system segment is divided into mammalian, bacteria, yeast, baculovirus/insect, and others. The cloning vector segment is divided into plasmid, phage, cosmid, Bacterial Artificial Chromosome (BAC), Yeast Artificial Chromosome (YAC), and Human Artificial Chromosome (HAC).
On the basis of application, the global recombinant DNA technology market is segmented into food and agriculture, health and disease, environment, and others.
On the basis of end-user, the global recombinant DNA technology market is segmented into biotechnology companies, academic and government research institutes, pharmaceuticals, and others.
Competitive Analysis by Major Key Players
Some of the key players in the global recombinant DNA technology market are F. Hoffmann-La Roche Ltd (Switzerland), Profacgen (U.S.), Amgen Inc. (U.S.), Novartis AG (Switzerland), Genscript Biotech (U.S.), Pfizer Inc. (U.S.), Novo Nordisk A/S (Denmark), Eli Lilly and Company (U.S.), Sanofi S.A. (France), Merck & Co., Inc. (U.S.), Biogen Inc. (U.S.), Biocon Limited (India), GlaxoSmithKline plc (UK), New England Biolabs (U.S.), Cibus (U.S.), Monsanto Company (U.S.), Horizon Discovery Group PLC (U.S.), Boehringer Ingelheim (Germany), and others.
Intended Audience
- Recombinant DNA Technology Test Kit Suppliers
- Recombinant DNA Technology Test Kit Manufacturers
- Research and Development (R&D) Companies
- Medical Research Laboratories
- Academic Medical Institutes and Universities
Browse Complete Premium Research Report https://www.marketresearchfuture.com/reports/recombinant-dna-technology-market-5845
Comprehensive Regional Analysis
The global recombinant DNA technology market is segmented into the Americas, Europe, Asia Pacific, and the Middle East and Africa.
The Americas region holds the largest market share of the global recombinant DNA technology market due to the presence of effective regulations pertaining to the approval of recombinant therapeutics and other Genetically Modified (GM) products. F. Hoffmann-La Roche Ltd, Amgen Inc., Novartis AG, Monsanto Company, Eli Lilly and Company, and Biogen Inc. are some of the major companies operating in this space that are responsible for the growth of the Americas recombinant DNA technology market.
Furthermore, there is an increasing need to improve the recombinant proteins production capacity by several folds in Europe. The increase in demand for effective therapeutics for the treatment of diseases and technological advancements in this sector are anticipated to drive the growth of the European recombinant DNA technology market.
Asia Pacific is expected to emerge as the fastest growing regional market for the global recombinant DNA technology market. The increasing awareness about the growing genetic diseases and disorders, developing healthcare infrastructure, increasing spending on healthcare, increasing government initiatives to improve public health, and advances in medical fields are driving the market growth.
The Middle East and Africa is expected to experience a limited growth due to less demand for genetic testing. The Middle East is growing significantly as compared to the African recombinant DNA technology market owing to the increase in aging population, innovations in genetic testing, and increase in the number of chronic disease cases.
Avail Discount at https://www.marketresearchfuture.com/check-discount/5845
About Market Research Future: MRFR team have supreme objective to provide the optimum quality market research and intelligence services to our clients. In order to stay updated with technology and work process of the industry, MRFR often plans & conducts meet with the industry experts and industrial visits for its research analyst members.
Contact:
Office No. 528, Amanora Chambers
Magarpatta Road, Hadapsar, Pune
+1 646 845 9312
Email: sales@marketresearchfuture.com
Your information will never be shared with any third party.